Additionally, saracatinib, a dual Src/Abl kinase inhibitor currently under clinical development for the treatment of Parkinson’s disease, psychosis, idiopathic pulmonary fibrosis and fibrodysplasia ossificans progressiva, demonstrated therapeutic potential in an IMQ-induced psoriasis model by suppressing MLKL phosphorylation and subsequent necroptotic cell death [71]. Here, MLKL is linked to pulmonary fibrosis.